CRH Investors Logo

CRH Medical Announces Q1 2011 Financial Results

  • Revenue increases 75%
    Company Reports First Profitable Quarter

VANCOUVER, BC, June 16, 2011– CRH Medical Corporation (CRM:TSX-V, CRMMF: OTCQX) announced today that it reported revenue for the three months ended March 31, 2011 of $1,249,835, an increase of 75% as compared to revenue of $715,622 for the three months ended March 31, 2010. The Company also announced that it reported net income of $66,369 for the three month ended March 31, 2011 compared to a net loss of $300,882 for the three months ended March 31, 2010.

Edward Wright, Chief Executive Officer of CRH Medical stated, “This quarter represents a significant milestone for CRH, our first ever profitable quarter. The strategies and tactics we have implemented are paying off, and we expect 2011 to be a profitable year.”

The Company’s March 31, 2011 financial report will be available on

About CRH Medical Corporation:

CRH Medical Corporation is a value added resource to the Gastroenterologist community, providing the CRH O’Regan System, as well as delivering related, clinical, marketing and operational support directly to its partner physicians. CRH utilizes its web based platform to connect doctors with patients as well as educating its ever increasing install base of physicians. CRH’s single use, disposable, hemorrhoid technology is safe and highly effective in treating hemorrhoid grades I – IV. The Company’s goal is to establish the CRH O’Regan System as the standard for hemorrhoid treatment.

The information in this news release contains so-called “forward-looking” statements. These include statements regarding CRH Medical’s expectations and plans relating to its business, statements about the CRH reaching its goal of profitability in 2011 and statements about CRH Medical’s expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as “anticipate”, “expect”, “intend”, “plan”, “will”, “we believe”, “CRH Medical believes”, “management believes”, and similar language. All forward-looking statements are based on CRH Medical’s current expectations and are subject to risks and uncertainties and to assumptions made. Assumptions include: (i) that the growth of CRH’s product sales will continue in a consistent manner; (ii) CRH’s costs will not escalate significantly; and (iii) CRH does not incur any extraordinary costs.
Important risk factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) we may need to raise additional capital to fund future operations; (ii) the policies of health insurance carriers in the United States may affect the amount of revenue the Company receives; (iii) the Company may not successfully market its products; (iv) changes in United States federal or state laws, rules, and regulations; (v) our senior management has been key to our growth, and we may be adversely affected if we lose any member of our senior management; (vi) economic dependence on suppliers and our contract manufacturer; (vii) changes in the industry and the economy may affect the Company’s business; (viii) evolving regulation of corporate governance and public disclosure may result in additional corporate expenses; (ix) we may not be able to attract Gastroenterologists and other licensed providers to purchase and use the CRH O’Regan System; (x) we may be subject to competition and technological risk which may impact the price and amount of product we can sell; (xi) we may be subject to product liability and medical malpractice claims, which may adversely affect our operations; (xii) our business may be impacted by health care reform in the United States; and (xiii) we may not have the expertise required to expand internationally. CRH Medical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them, except as required by law.

For further information call Dean Linden, Corporate Communications, CRH Medical Corporation at 604.633.1440 or Additional information may also be found by visiting the Company’s website at or the SEDAR website at
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.